PMID- 30507318
OWN - NLM
STAT- MEDLINE
DCOM- 20190812
LR  - 20211204
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 129
IP  - 6
DP  - 2019 Jun
TI  - Perampanel in patients with brain tumor-related epilepsy in real-life clinical 
      practice: a retrospective analysis.
PG  - 593-597
LID - 10.1080/00207454.2018.1555160 [doi]
AB  - INTRODUCTION: Epilepsy occurs in 35-70% of patients with gliomas; glutamate plays 
      a central role via AMPA-receptor activation, which is involved both in seizure 
      activity and tumor growth. We conducted a retrospective study on brain 
      tumor-related epilepsy patients (BTRE) treated with perampanel in add-on (PER) 
      for 12 months, to evaluate efficacy and tollerability, according to real-life 
      clinical practice. MATERIALS AND METHODS: Medical records of eleven patients (9 
      males, mean age 54 years) with glioma and epilepsy treated with PER in add-on, 
      for inadequate seizure control or adverse events (AEs) from previous 
      antiepileptic drugs (AEDs) therapy, were reviewed. Data collected included: tumor 
      history, molecular factors, systemic therapy, type and number of seizures and 
      concomitant AEDs, and AEs. RESULTS: After 12 months of PER therapy, five patients 
      were seizure-free, 4 had a seizure reduction >/=50% and the seizure frequency was 
      unchanged in 2 patients. Responder rate was 81.8%. Two patients reported AEs; PER 
      dose was reduced only in the one case. The final median dose of PER was 
      7.3 mg/day. We didn't find statistically significant differences in the 
      comparison between mean values pre, mean values post and the average of 
      decreasing number of seizures related to: histology, presence/absence of 
      chemotherapy, radiotherapy, progression disease, KPS, IDH1, MGMT. DISCUSSION: 
      Despite the limitations due to small number of patients in a retrospective study, 
      the high rate of responder and seizure-free patients suggest that PER could be a 
      therapeutic option in BTRE. Prospective controlled studies are needed to confirm 
      our data.
FAU - Maschio, Marta
AU  - Maschio M
AD  - a Center for Tumor-related Epilepsy, UOSD Neurology , Regina Elena National 
      Cancer Institute , Rome , Italy.
FAU - Pauletto, Giada
AU  - Pauletto G
AD  - b Neurology Unit, Department of Neurosciences , S. Maria della Misericordia 
      University Hospital , Udine , Italy.
FAU - Zarabla, Alessia
AU  - Zarabla A
AD  - a Center for Tumor-related Epilepsy, UOSD Neurology , Regina Elena National 
      Cancer Institute , Rome , Italy.
FAU - Maialetti, Andrea
AU  - Maialetti A
AD  - a Center for Tumor-related Epilepsy, UOSD Neurology , Regina Elena National 
      Cancer Institute , Rome , Italy.
FAU - Ius, Tamara
AU  - Ius T
AD  - b Neurology Unit, Department of Neurosciences , S. Maria della Misericordia 
      University Hospital , Udine , Italy.
FAU - Villani, Veronica
AU  - Villani V
AD  - c UOSD Neurology , Regina Elena National Cancer Institute , Rome , Italy.
FAU - Fabi, Alessandra
AU  - Fabi A
AD  - d Oncology Unit , Regina Elena National Cancer Institute , Rome , Italy.
FAU - Koudriavtseva, Tatiana
AU  - Koudriavtseva T
AD  - c UOSD Neurology , Regina Elena National Cancer Institute , Rome , Italy.
FAU - Giannarelli, Diana
AU  - Giannarelli D
AD  - e Biostatistic Unit , Regina Elena National Cancer Institute , Rome , Italy.
LA  - eng
PT  - Journal Article
DEP - 20181226
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
MH  - Anticonvulsants/adverse effects/therapeutic use
MH  - Brain Neoplasms/*complications
MH  - Epilepsy/*complications/*drug therapy
MH  - Female
MH  - Glioma/complications
MH  - Humans
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Nitriles
MH  - Pyridones/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiepileptic drugs
OT  - brain tumor-related epilepsy
OT  - molecular factors
OT  - perampanel
OT  - responder rate
EDAT- 2018/12/07 06:00
MHDA- 2019/08/14 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1080/00207454.2018.1555160 [doi]
PST - ppublish
SO  - Int J Neurosci. 2019 Jun;129(6):593-597. doi: 10.1080/00207454.2018.1555160. Epub 
      2018 Dec 26.